EBI

Exponential Biotherapies (EBI) is a clinical-stage biopharmaceutical company focused on developing a novel class of therapeutic agents derived from human pregnancy hormones. The company's lead candidate, EA-230, is a first-in-class synthetic polypeptide designed to improve hemodynamic stability and reduce microvascular barrier dysfunction in critically ill patients. EBI's primary clinical focus is on preventing and treating postoperative complications following major surgeries, such as cardiac procedures, where systemic inflammatory responses often lead to organ damage. Beyond surgical stress, the company is exploring applications for its peptide platform in acute systemic inflammation, sepsis, and tissue damage resulting from irradiation therapy. EBI operates with a presence in both the United States and the Netherlands, leveraging research from Radboud University Medical Centre.